Freeslate CM Protégé PharmD System Now Automates Process Chemistry and Preformulation Screens on a Single Platform

Freeslate enhances CM Protégé PharmD System, enabling reaction screening and optimization capabilities to create a single platform for small molecule drug development

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
With the new capabilities of the CM Protégé PharmD System, our customers can drive productivity in process chemistry, as well as preformulation, with a single system.

Sunnyvale, CA (PRWEB) September 04, 2014

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced the CM Protégé PharmD System will now support reaction screening and optimization. The CM Protégé PharmD System is an automated platform that supports a wide range of drug development applications, including high throughput polymorph, salt, co-crystal, and solubility screens of active pharmaceutical ingredients (API), and now process chemistry as well.

With the new capabilities on the CM Protégé PharmD System, a researcher can screen hundreds of reaction conditions (e.g., temperature, pressure, concentration) and variables (e.g., acids, bases, catalysts, ligands, solvents) per day to quickly optimize process parameters using minimal amounts of materials. Because of the greater throughput, a scientist can explore reaction parameters outside those used in conventional experimentation, reducing development risk and allowing for non-intuitive discoveries.

“Our customers are often trying to push innovation in multiple drug development application areas,” said John S. Senaldi, President and CEO of Freeslate. “With the new capabilities of the CM Protégé PharmD System, our customers can drive productivity in process chemistry, as well as preformulation, with a single system.”

As a fully automated platform for small molecule drug development, the CM Protégé PharmD System combines liquid handling of aqueous/viscous liquids and slurries with automated heating, vortexing, and stirring to support reaction screening and optimization. When combined with a Freeslate Screening Pressure Reactor, high pressure and high temperature reactions can be explored as well. The system uses Freeslate’s Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its logical recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting.

About Freeslate

Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.


Contact